Revolution Medicines (RVMD) Cash & Equivalents (2019 - 2026)

Revolution Medicines' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $440.9 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 32.19% year-over-year to $440.9 million in Q1 2026; TTM through Mar 2026 was $440.9 million, a 32.19% increase from a year earlier, with the FY2025 full-year figure at $383.7 million, down 29.34% from the prior year.
• Cash & Equivalents climbed to $440.9 million in Q1 2026 per RVMD's latest filing, from $383.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $696.1 million in Q4 2023 and bottomed at $97.7 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $333.6 million (2025), against an average of $323.1 million.
• Across the five-year window, Cash & Equivalents plunged 72.22% in 2022 and surged 337.43% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $161.4 million in 2022, then soared by 331.29% to $696.1 million in 2023, then retreated by 21.99% to $543.1 million in 2024, then dropped by 29.34% to $383.7 million in 2025, then climbed by 14.9% to $440.9 million in 2026.
• Per Business Quant, the three latest RVMD Cash & Equivalents figures stand at $440.9 million (Q1 2026), $383.7 million (Q4 2025), and $217.4 million (Q3 2025).